Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas

Trial Profile

Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 04 Mar 2013 Planned End Date changed from 1 Apr 2012 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Additional lead trial investigators and associated centres added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top